Enrichment and Quantitative Determination of 5-(Hydroxymethyl)-2′-deoxycytidine, 5-(Formyl)-2′-deoxycytidine, and 5-(Carboxyl)-2′-deoxycytidine in Human Urine of Breast Cancer Patients by Magnetic Hyper-Cross-Linked Microporous Polymers Based on Polyionic Liquid

2018 ◽  
Vol 90 (6) ◽  
pp. 3906-3913 ◽  
Author(s):  
Mengzhe Guo ◽  
Liyan Zhang ◽  
Yan Du ◽  
Wencheng Du ◽  
Dantong Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantitative Determination ◽  
Cancer Patients ◽  
Human Urine ◽  
Breast Cancer Patients ◽  
Microporous Polymers ◽  
Polyionic Liquid

scholarly journals Determination of O6-Methylguanine in Dried Blood Spot of Breast Cancer Patients After Cyclophosphamide Administration

Heliyon ◽  
2021 ◽  
pp. e07558
Author(s):  
Yahdiana Harahap ◽  
Athalia Theda Tanujaya ◽  
Farhan Nurahman ◽  
Aurelia Maria Vianney ◽  
Denni Joko Purwanto
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Dried Blood Spot ◽  
Breast Cancer Patients ◽  
Cyclophosphamide Administration ◽  
Blood Spot

scholarly journals RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients

2006 ◽  
Vol 17 (3) ◽  
pp. 424-428 ◽  
Author(s):  
L. Mercatali ◽  
V. Valenti ◽  
D. Calistri ◽  
S. Calpona ◽  
G. Rosti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Cancer Patients ◽  
Rt Pcr ◽  
Healthy Donors

scholarly journals Determination of the Complex between Urokinase and Its Type-1 Inhibitor in Plasma from Healthy Donors and Breast Cancer Patients

1999 ◽  
Vol 45 (8) ◽  
pp. 1206-1213 ◽  
Author(s):  
Anders N Pedersen ◽  
Nils Brünner ◽  
Gunilla Høyer-Hansen ◽  
Peter Hamer ◽  
David Jarosz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Detection Limit ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Healthy Donors ◽  
Pai 1 ◽  
Healthy Females ◽  
Assay Detection

Abstract Background: The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) is formed exclusively from the active forms of these components; thus, the complex concentration in a biological sample may reflect the ongoing degree of plasminogen activation. Our aim was to establish an ELISA for specific quantification of the uPA:PAI-1 complex in plasma of healthy donors and breast cancer patients. Methods: A kinetic sandwich format immunoassay was developed, validated, and applied to plasma from 19 advanced-stage breast cancer patients, 39 age-matched healthy women, and 31 men. Results: The assay detection limit was <2 ng/L, and the detection of complex in plasma was validated using immunoabsorption, competition, and recovery tests. Eighteen cancer patients had a measurable complex concentration (median, 68 ng/L; range, <16 to 8700 ng/L), whereas for healthy females and males the median signal values were below the detection limit (median, <16 ng/L; range, <16 to 200 ng/L; P <0.0001). For patient plasma, a comparison with total uPA and PAI-1 showed that the complex represented a variable, minor fraction of the uPA and PAI-1 concentrations of each sample. Conclusion: The reported ELISA enables detection of the uPA:PAI-1 complex in blood and, therefore, the evaluation of the complex as a prognostic marker in cancer.

Determination of Serum Methylparaben Concentrations of Bangladeshi Breast Cancer Patients by RP-HPLC

2017 ◽  
Vol 7 (5) ◽  
pp. 589-595 ◽  
Author(s):  
Sanjida Afrin ◽  
Hasina Akhter Simol ◽  
Gazi Nurun Nahar Sultana ◽  
Md. Sazedul Islam ◽  
Papia Haque ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Rp Hplc

Clinical studies of p53 in treatment and benefit of breast cancer patients.

1999 ◽  
pp. 51-59 ◽  
Author(s):  
J Bergh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Predictive Factor ◽  
Clinical Studies ◽  
Review Article ◽  
Breast Cancer Patients ◽  
National Library ◽  
Specific Therapy ◽  
P53 Status

This article describes p53 as a prognostic and predictive factor, together with some information on how best to determine the p53 status. By December 1998, 13,000 articles on p53 were identified on Pub Med, the National Library of Medicine. Within one week a further 62 articles were recorded making it difficult to give the complete p53 story. This review article will focus on discussing p53 in relation to its predictive potential. So far, no firm conclusions can be made based on the articles studied. This may be, in part, because many studies have used less than optimal techniques for determination of the p53 status, together with the fact that the studies lacked power to detect a potential difference in outcome from specific therapy in relation to p53 status.

Sign in / Sign up

Export Citation Format

Share Document